CRON vs. CGC, USNA, MNMD, BTMD, ACB, CDXC, MGNX, AORT, INVA, and LQDA
Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Canopy Growth (CGC), USANA Health Sciences (USNA), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), MacroGenics (MGNX), Artivion (AORT), Innoviva (INVA), and Liquidia (LQDA). These companies are all part of the "medical" sector.
Canopy Growth (NASDAQ:CGC) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking.
Cronos Group has a net margin of -61.31% compared to Cronos Group's net margin of -326.75%. Canopy Growth's return on equity of -3.06% beat Cronos Group's return on equity.
Canopy Growth currently has a consensus price target of $4.87, indicating a potential downside of 48.45%. Cronos Group has a consensus price target of $2.83, indicating a potential downside of 2.63%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Canopy Growth.
Cronos Group has lower revenue, but higher earnings than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Cronos Group received 444 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 61.21% of users gave Cronos Group an outperform vote while only 19.80% of users gave Canopy Growth an outperform vote.
3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 0.4% of Canopy Growth shares are owned by company insiders. Comparatively, 2.0% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Canopy Growth has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
In the previous week, Canopy Growth had 2 more articles in the media than Cronos Group. MarketBeat recorded 18 mentions for Canopy Growth and 16 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.93 beat Canopy Growth's score of 0.40 indicating that Canopy Growth is being referred to more favorably in the media.
Summary
Cronos Group beats Canopy Growth on 14 of the 18 factors compared between the two stocks.
Get Cronos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cronos Group Competitors List
Related Companies and Tools
